Jihad Slim · Peerford

PeerfordResearch intelligence

Jihad Slim · Peerford

What they work on

From the classification of each paper

Subfields

Infectious Diseases778%
Emergency Medicine333%
Epidemiology222%
Public Health, Environmental and Occupational Health222%
Surgery222%
Critical Care and Intensive Care Medicine111%
Hematology111%
Molecular Biology111%
Pathology and Forensic Medicine111%
Pharmacology111%

Health Sciences
Life Sciences

Topics most written on

HIV/AIDS drug development and treatment3
Clostridium difficile and Clostridium perfringens research2
HIV-related health complications and treatments2
HIV/AIDS Research and Interventions2
Streptococcal Infections and Treatments2
Antimicrobial Resistance in Staphylococcus1
Autoimmune and Inflammatory Disorders Research1
COVID-19 Clinical Research Studies1
Drug-Induced Adverse Reactions1
Helicobacter pylori-related gastroenterology studies1
Hematological disorders and diagnostics1
HIV Research and Treatment1

Who they write with

Their most frequent co-authors, and the papers those co-authors share

Where their co-authors are

100% of their papers have a co-author abroad

papers co-written1234567Home

Most frequent partner countries

United States9
United Kingdom4
South Africa3
Argentina2
Australia2
Ethiopia2
Puerto Rico2
Taiwan2

Papers with at least one author in that country.

Institutions written with most

Saint Michael's Medical CenterUS9 papers
Suburban Community HospitalUS3 papers
New York Medical CollegeUS3 papers
UNSW SydneyAU2 papers
Blizard InstituteGB2 papers
Chelsea and Westminster HospitalGB2 papers
Fundación HuéspedAR2 papers
Holdsworth House Medical PracticeAU2 papers
Hospital Ramos MejíaAR2 papers
Kaohsiung Veterans General HospitalTW2 papers

Where they publish

Cureus4
Clinical Infectious Diseases1
Future Virology1
Gastroenterology Research and Practice1
Journal of Infection1
The Lancet1

How it can be read

Development goals addressed

From each paper’s title and abstract

3Good health and well-being9

Most cited

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Clinical Infectious Diseases3
2020170 citationsWorld top 10%Open access · Hybrid
Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials
Journal of Infection3
201240 citationsWorld top 10%